.avif)
.avif)
Kura Oncology Email Format
Biotechnology Research
・
51-200 employees
・
San Diego, CA, USA
Kura Oncology is a clinical-stage biopharmaceutical company developing precision small-molecule therapies targeting cancer signaling pathways and genetic drivers to improve patient outcomes.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
firstinitiallast@kuraoncology.com
Company Overview
Industry
Biotechnology Research
Founded
2014
Headquarters
San Diego, CA, USA
Revenue
$25M-$50M
FUNDING Stage
Public
Website
Key Executives
Troy Wilson, Ph.D., J.D. (President & Chief Executive Officer), Thomas Doyle (Senior Vice President, Finance & Accounting and Principal Accounting Officer), Kathleen Ford (Chief Operating Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Kura Oncology?
Kura Oncology uses the firstinitiallast format on kuraoncology.com, so Jane Smith would be jsmith@kuraoncology.com.
What FDA-approved therapy has Kura Oncology brought to market for acute myeloid leukemia?
Kura Oncology, in collaboration with Kyowa Kirin, received FDA approval for KOMZIFTI (ziftomenib), a once-daily oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia.
Who leads Kura Oncology as its chief executive?
Troy Wilson, Ph.D., J.D. serves as President and Chief Executive Officer of Kura Oncology, with Kathleen Ford as Chief Operating Officer and Thomas Doyle as Senior Vice President of Finance and Accounting.
How can I find and verify the contact details of a Kura Oncology employee for outreach?
Tools like Clay can help you verify and enrich contact information for Kura Oncology employees by applying the firstinitiallast email format at kuraoncology.com, so you can reach the right person with confidence.
Beyond ziftomenib, what other drug candidates are in the Kura Oncology pipeline?
Kura Oncology's pipeline includes tipifarnib, a farnesyl transferase inhibitor being studied in HRAS-mutant head and neck squamous cell carcinoma, and KO-2806, a next-generation menin inhibitor, both targeting cancer signaling pathways.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating